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ABSTRACT
 
—Several reports have indicated that prolactin-secreting cells (PRL cells) are generated from
growth hormone-secreting cells (GH cells). We have shown that treatment with a combination of epidermal
growth factor (EGF), insulin, and estradiol-17
 
β
 
 (E
 
2
 
) induces the appearance of PRL cells in pituitary tumor
GH3 cells. The aim of the present study was to clarify the involvement of mitosis in the cytogenesis of
PRL cells in rat pituitary and GH3 cells. The effects of the treatment with EGF, insulin and E
 
2
 
 on DNA-
replication were studied by detecting the uptake of bromodeoxyuridine (BrdU) into the nucleus. In cultured
rat pituitary cells, BrdU-labeled PRL cells were observed irrespective of the hormone treatment. In GH3
cells, BrdU-labeled GH cells and mammosomatotrophs (MS cells) were detected; BrdU-labeled PRL cells
were not detected, however, when GH3 cells were treated with BrdU for 3 hr and then immediately exam-
ined for BrdU-labeling. BrdU-labeled PRL cells were found only when GH3 cells treated with BrdU were
allowed to grow for another 3 days. This finding suggests that during the additional 3-day culture, BrdU-
labeled PRL cells were generated from BrdU-labeled cells other than PRL cells. These results indicate that
PRL cells are transdifferentiated from GH cells or MS cells in GH3 cells by a combined treatment with EGF,
insulin and E
 
2
 
, while PRL cells in rat pituitaries are able to proliferate in response to the hormone treat-
ment. Thus, there may be two pathways for cytogenesis of PRL cells: the transdifferentiation of GH cells
or MS cells, and a self-duplication of PRL cells.
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INTRODUCTION
 
Prolactin-secreting cells (PRL cells) are generated from
preexisting growth hormone-secreting cells (GH cells) in the
initial cytogenesis of pituitary cells during the fetal period in
mice (Behringer 
 
et al.
 
, 1988; Borrelli 
 
et al
 
., 1989). We have
recently demonstrated that PRL cells differentiate from GH
cells through mammosomatotrophs (MS cells), which syn-
thesize and secrete both GH and PRL in response to a com-
bined treatment of epidermal growth factor (EGF), insulin
and estradiol-17
 
β
 
 (E
 
2
 
) in rat pituitary tumor GH3 cells
(Kakeya 
 
et al
 
., 2000). In contrast, the proliferation of PRL
cells is a well-known event in the rat and mouse pituitary
gland (Takahashi, 1995). The highest mitotic activity of PRL
cells is observed at estrus in the female rat pituitary (Taka-
hashi 
 
et al
 
., 1984; Oishi 
 
et al
 
., 1993). As estrogen treatment
stimulates the proliferation of PRL cells (Lloyd 
 
et al
 
., 1975;
Takahashi and Kawashima, 1987; Oomizu 
 
et al
 
., 2000), the
high proliferating activity of PRL cells is caused by the
increase in estrogen secretion during the proestrous and
estrous days. Thus, it is evident that PRL cells are generated
from preexisting PRL cells through mitosis under estrogenic
stimulation (self-duplication) 
 
in vivo
 
. The above findings indi-
cate that there are two pathways for the cytogenesis of PRL
cells: the transdifferentiation of GH cells into PRL cells, and
the self-duplication of preexisting PRL cells. However, it
remains unclear whether the former pathway operating in
GH3 cells requires a mitotic process. The present study
attempted to clarify the involvement of mitosis of pituitary
cells in the cytogenesis of PRL cells in GH3 cells.
 
MATERIALS AND METHODS
 
Cell cultures
 
Pituitary cells
 
Two-month-old male rats of the Sprague-Dawley strain
obtained from CLEA Japan (Osaka, Japan) were used. Anterior
pituitary cells were dispersed by trypsin/DNase digestion following
the method of Oomizu 
 
et al
 
. (1998). Cell yield was estimated by
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counting the cells with a haemocytometer. The viability of cells was
checked using a trypan blue exclusion test. The dispersed cells
were seeded at a density of 3
 
×
 
10
 
5
 
 cells/ml in a 1:1 mixture of Dul-
becco’s modified Eagle’s medium and Ham’s F-12 medium (DME/
F12, Sigma Chemical Co., St. Louis, MO) supplemented with 10%
(v/v) fetal bovine serum (FBS; Gibco BRL, Life Technologies, Inc.,
Rockville, MD,) on poly-L-lysine (Sigma Chemical Co.)-coated glass
coverslips (diameter 13 mm, Matsunami Glass Ind., Osaka, Japan)
in a 24-well plate (Becton Dickinson, Lincoln Park, NJ) for 3 days
before the hormone treatment. After a 3-day culture, the pituitary
cells were maintained in serum-free DME/F12 medium supple-
mented with hydrocortisone (100 
 
µ
 
g/l), 3,5,3’-triiodothyronine (400
ng/l), transferrin (10 mg/l), bovine glucagon (10 ng/l), EGF (10 ng/
l), parathyroid hormone (200 ng/l), and sodium selenite (5 
 
µ
 
g/l).
After the culture under the serum-free condition for 2 days, the pitu-
itary cells were treated with a combination of EGF (10 nM), insulin
(300 nM), and E
 
2
 
 (1 nM) for 6 hr or 3 days. These concentrations
were determined following the previous reports (Scammell 
 
et al
 
.,
1986; Kakeya 
 
et al
 
., 2000). EGF, insulin and E
 
2
 
 were obtained from
Sigma Chemical Co. Experiments were performed under the Guide-
line of Animal Experimentation, Faculty of Science, Okayama Uni-
versity.
 
GH3 cells
 
GH3 cells, obtained from the Japan Health Sciences Founda-
tion, Osaka, Japan, were maintained in DME/F12 medium supple-
mented
 
l
 
 with 5% (v/v) FBS at 37
 
°
 
C in a humidified atmosphere of
5% CO
 
2
 
 and 95% air. GH3 cells were cultured in a 24-well plate at
a density of 5
 
×
 
10
 
4
 
 cells/ml. EGF (10 nM), insulin (300 nM), E
 
2
 
 (1
nM) or a combination of EGF, insulin and E
 
2
 
 were added to the cul-
ture medium for 6 days or 9 days. Each group was consisted of
three wells, and the medium was changed every 2 days. Indepen-
dent experiments were performed three times.
 
Detection of DNA-synthesizing cells
 
DNA-synthesizing cells were identified by monitoring the
uptake of 5-bromo-2’-deoxyuridine (BrdU; Amersham, Buckingham-
shire, UK), a thymidine analogue, into the cell nucleus following the
previous report (Kakeya 
 
et al
 
., 2000). BrdU solution from a cell pro-
liferation kit (Amersham) was added into the culture medium (3 mg/
ml) for 3 hr on day 6 or day 9 of the culture. The half of the pituitary
cells and GH3 cells treated with BrdU on day 6 were cultured for
another 3 days. All cells were rinsed with 0.01M phosphate-buffered
saline (PBS; pH 7.4) and fixed in Bouin’s solution for 2 hr at room
temperature. The cells were dehydrated through a graded series of
ethanol concentrations, left in xylene for 5 min, and then rehy-
drated. Nonspecific immunoreactivity was blocked by incubating the
glass coverslips with 1% low-fat dried milk (w/v) in PBS for 30 min
at room temperature. The cells were then incubated with mono-
clonal antibodies raised against BrdU (Amersham) for 1 hr at room
temperature in a humidified box. The cells were washed three times
with PBS. They were then incubated with peroxidase-conjugated
anti-mouse immunoglobulin G (IgG) as a second antibody for 30
min at room temperature. BrdU immunoreactivity was detected
using 3,3’-diaminobenzidine tetrahydrochloride (DAB, Sigma Chem-
ical Co.) following the method of Hsu and Soban (1982). After the
BrdU detection, the coverslips were incubated in 0.3% H
 
2
 
O
 
2
 
-meth-
anol to inactivate the peroxidase of the second antibodies (peroxi-
dase-conjugated anti-mouse IgG) for the following immunostaining.
 
Dual-detection of GH and PRL
 
Dual-detection of GH and PRL in rat pituitary cells was per-
formed with two primary antisera generated from animals of differ-
ent species. The pituitary cells were first incubated in antiserum
against rat PRL (1:4000, NIDDK-anti-rPRL-IC-5, NIH, Bethesda,
MD) in a humidified box for 1 hr at room temperature. Detection of
PRL was carried out using Vectastain ABC Kit (Vector Laboratories,
Inc., Burlingame, CA) and DAB as a chromogen. Subsequent
detection of GH was carried out using monkey anti-GH antiserum
(1:500, NIDDK-anti-rGH-IC-1, NIH) and tetramethylrhodamine
isothiocyanate (TRITC)-labeled goat anti-monkey immunoglobulin
(IgG) (E-Y Laboratories, San Mateo, CA).
Dual immunofluorescent detection of GH and PRL in GH3
cells was performed two primary antisera used for the rat pituitary
cells. The cells were first incubated with monkey antiserum against
rat GH (1:500, NIDDK-anti-rGH-IC-1) in a humidified box for 1 hr at
room temperature, rinsed with PBS three times, and then incubated
in rabbit antiserum against rat PRL (1:1000, NIDDK-anti-rPRL-IC-
5). The immunostained coverslips were then washed three times
with PBS, incubated in TRITC-labeled goat anti-monkey IgG and
then fluoresceinisothiocyanate (FITC)-labeled goat anti-rabbit IgG
 
Fig. 1.
 
Percentages of GH, PRL, and other cells (Other) that
secrete neither GH nor PRL in adult male rat pituitary cells. Pituitary
cells were cultured in the control medium or in medium supple-
mented with a combination of EGF, insulin and E
 
2
 
 for 1 day (day 6)
or 3 days (day 9). MS cells were not detected under the present
condition. The proportions of GH, PRL, and other cells differed
between the control and hormone-treated groups on day 9 (p<0.01).
In both control and hormone-treated groups, the proportions of GH
cells, PRL cells and other cells differed between day 6 and day 9
(control, p<0.05; the hormone-treated, p<0.01). Data are expressed
as the mean ± standard errors of the means (SEM) of three inde-
pendent experiments.
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(E-Y Laboratories) in a humidified box for 30 min at room tempera-
ture.
Immunofluorescence of each hormone and light field images
of BrdU-labeled cells were observed with a laser scanning confocal
fluorescent microscope (MRC-600, Bio-Rad Laboratories, Rich-
mond, CA). The fields were scanned across the coverslip to avoid
overlap. Each group consisted of three coverslips, and more than
500 cells were observed from each coverslip. The percentage of
BrdU-labeled hormone-synthesizing cells was determined by count-
ing the number of those cells against the total cells observed.
The specificity of the antisera for immunocytochemistry was
evaluated as follows: (1) incubation of normal rabbit serum instead
of each antiserum; (2) preabsorption of each antiserum with corre-
sponding purified antigens (NIDDK rGH I-5 or rPRL I-5, NIH, 50 
 
µ
 
g/
ml diluted antiserum) 24 hr before the immunostaining. No immun-
ostaining was observed in these controls.
 
Statistics
 
Statistical significance of the difference between the means
was assessed with one-way analysis of variance (ANOVA). Three
independent experiments were performed in each study. The rela-
tive number of GH, MS, and PRL cells was analyzed by the method
of R x C test of independence using G-test (Sokal and Rohlf, 1981).
Values of the mean and standard errors were calculated from the
three independent experiments.
 
RESULTS
Percentages of GH, PRL, MS and the other cells
 
The cultured pituitary cell population under the serum-
free condition was heterogeneous, consisting of various
types of hormone-secreting cells, with GH and PRL cells
accounting for approximately one-third of the total pituitary
cells (Fig. 1). Treatment with a combination of EGF, insulin,
and E
 
2
 
 on pituitary cells induced a slight change in the pro-
portion of GH, PRL, and other cells that secrete neither GH
 
Fig. 2.
 
Percentages of GH, MS, and PRL cells in GH3 cells. GH3
cells were cultured in the control medium or in medium supple-
mented with a combination of EGF, insulin and E
 
2
 
 for 6 days or 9
days. The hormone treatment induced the appearance of PRL cells.
The proportions of GH, MS, PRL, and other cells differed between
the control and hormone-treated groups on day 6 (p<0.001) and day
9 (p<0.01), respectively. In both the control and hormone-treated
groups, the proportions of GH, PRL, and other cells differed
between day 6 and day 9 (p<0.05, in both groups). Data are
expressed as the mean
 
±
 
SEM of three independent experiments.
ND: not detected.
 
Fig. 3.
 
Typical view of triple-immunostaining for BrdU, PRL and
GH in cultured rat pituitary cells. Pituitary cells were cultured in
medium supplemented with a combination of EGF, insulin and E
 
2
 
for 3 days. Pituitary cells were stained with anti-rat GH antiserum by
fluorescence immunocytochemistry (A), and with anti-rat PRL
antiserum and anti-BrdU antiserum by conventional immunocy-
tochemistry (B). A and B are the same field of a culture plate. Immu-
noreactive BrdU was detected in a nucleus, and immunoreactive
GH and PRL were detected in the cytoplasm. An arrow indicates
GH cell and an arrowhead indicates BrdU-labeled PRL cell. MS
cells in pituitary cells were not detected in the present study. Bar=20
 
µ
 
m
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nor PRL relative to the control on day 9 (Fig. 1, p<0.01).
During a 3-day culture, the proportions of GH, PRL, and
other cells varied in the control and hormone-treatment
groups, regardless of treatment (control, p<0.05; the hor-
mone-treated, p<0.01), and the percentages of GH cells
declined in both groups.
GH3 cells consist of GH and MS cells, which secrete
both GH and PRL, but PRL cells were not detected under
the control culture condition (5% FBS supplemented). Treat-
ment with a combination of EGF, insulin, and E
 
2
 
 stimulated
the appearance of PRL cells in GH3 cells and altered the
proportion of GH, MS, and PRL cells relative to the control
on days 6 and 9 of culture (Fig. 2, p<0.001 and p<0.01,
respectively). During a 3-day culture, the proportions of GH,
MS, PRL, and other cells varied in the control and hormone-
treatment groups (p<0.05, in both groups).
 
DNA-replication in pituitary cells and GH3 cells
 
Pituitary cells
 
DNA-synthesizing pituitary cells, immunocytochemically
identified using the BrdU-labeling method, were observed in
 
Fig. 4.
 
Percentages of BrdU-labeled cells in pituitary cells. Pituitary
cells were cultured in the control medium or in medium supple-
mented with a combination of EGF, insulin and E
 
2
 
 on day 6 of the
culture. Pulse labeling of BrdU for 3 hr was performed on day 6 or
day 9 of the culture, and immediately after the labeling the pituitary
cells were fixed, and then BrdU-labeled cells were immunocy-
tochemically detected (Groups I and III). The other group of pituitary
cells treated with BrdU on day 6 were cultured, and was analyzed
for BrdU-labeling on day 9 (Group II). Data are expressed as the
mean 
 
±
 
 SEM of three independent experiments. * P<0.05, ***
P<0.001, compared with the control of the same group.
 
Fig. 5.
 
Typical view of triple-immunostaining for BrdU, PRL and
GH in GH3 cells. GH3 cells which were cultured in medium supple-
mented with a combination of EGF, insulin and E
 
2
 
 , were treated
with BrdU for 3 hr on day 6, and were allowed to grow for another 3
days. On day 9 of the culture, GH3 cells were fixed, and were
stained with anti-rat GH antiserum (A), anti-rat PRL antiserum (B),
and anti-BrdU antiserum (C). Three photographs are the same field
of a culture plate. Photographs (A and B) are immunofluorescent
images, and photograph (C) is a bright-field image taken by confo-
cal microscopy. Immunoreactive BrdU was visualized by DAB color-
ation and detected in a nucleus. The cells designated by arrows (#1,
#2 and #3) were labeled with BrdU (C).The #1 cell is a PRL cell, and
the #3 cell is a GH cell. The #2 cell, which contained immunoreac-
tive GH (A) and PRL (B) in the cytoplasm, is an MS cell. Bar=10 
 
µ
 
m
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GH and PRL cells (Fig. 3), indicating that pituitary GH cells
and PRL cells have the ability to proliferate under the culture
conditions employed. Pituitary cells were treated with BrdU
solution for 3 hr on day 6 or day 9 of the culture, and were
examined immediately after the treatment. BrdU-labeled
cells were immunocytochemically detected (Fig. 4, Group I
and III). The other group of pituitary cells that had been
treated with BrdU on day 6 was cultured until day 9 (Fig.4,
Group II). BrdU-labeled GH cells and PRL cells were
detected regardless of the hormone treatment on days 6
and 9. The additional 3-day culture of GH3 cells after being
treated with a combination of EGF, insulin, and E
 
2
 
 did not
affect the percentage of BrdU-labeled PRL cells.
 
GH3 cells
 
Pulse BrdU-labeling for 3 hr was performed as
described in the pituitary cells. Fig. 5 shows typical views of
BrdU-labeled PRL (#1 cell), GH (#3 cell), and MS cells (#2
cell) in GH3 cells treated with a combination of EGF, insulin,
and E
 
2
 
. Fig. 6 illustrates the percentage of BrdU-labeled
GH3 cells. BrdU-labeled GH cells and MS cells were
detected in both the control and hormone-treated groups,
but BrdU-labeled PRL cells were not detected, when BrdU-
labeling was performed on days 6 and 9 (Groups I and III).
In contrast, when GH3 cells treated with BrdU on day 6 were
cultured for another 3 days (Group II), BrdU-labeled PRL
cells were detected, and the percentages of BrdU-labeled
MS cells and PRL cells increased relative to those of GH3
cells in the control group (p<0.05, p<0.01, respectively),
while those of BrdU-labeled GH cells decreased (P<0.05).
 
DISCUSSION
 
Transdifferentiation of GH cells into PRL cells had been
previously suggested in several reports (Hoeffler 
 
et al
 
.,
1985; Frawley and Boockfor, 1991; Takahashi, 1995). Initial
differentiation of PRL cells from GH cells is a post-mitotic
process in the immature mouse pituitary gland (Behringer 
 
et
al
 
., 1988; Borrelli 
 
et al
 
., 1989). Similarly, we have suggested
that the transdifferentiation of GH cells into PRL cells can be
induced by treatment of GH3 cells with a combination of
EGF, insulin, and E
 
2
 
 (Kakeya 
 
et al.
 
, 2000). However, it
remains unclear whether this appearance of PRL cells is a
postmitotic event, as reported in the case of mouse pituitary
PRL cells. Therefore, we attempted to clarify the involve-
ment of cell division in the process of PRL cell differentiation
observed in GH3 cells. BrdU-labeling was performed to
study the DNA-synthesizing cells. The result of the present
study demonstrate that PRL cells of GH3 cells cannot be
immediately labeled with BrdU, but that BrdU-labeled PRL
cells will appear with an additional 3 day-culture. This finding
indicates that PRL cells of GH3 cells lose their ability to syn-
thesize DNA and likely their ability to undergo mitosis. Goda
 
et al
 
. (1998) have reported that in the pituitary tumor MtT/S
cell line, PRL cells fail to replicate their DNA, which is in
agreement with the present study. Despite the inability of the
PRL cells to replicate their DNA, BrdU-labeled PRL cells
were detected after the additional culture, suggesting that
BrdU-labeled GH3 cells other than the PRL cells were trans-
differentiated into PRL-only secretors in response to the
treatment with a combination of EGF, insulin, and E
 
2
 
.
GH3 cell-populations usually consist of GH and MS
cells under the culture conditions employed with the growth
of GH3 cells being stimulated (in the medium containing 5%
FBS); in contrast, EGF treatment with insulin and/or E
 
2
 
 stim-
ulates the appearance of PRL cells (Kakeya 
 
et al
 
., 2000).
The appearance of BrdU-labeled PRL cells after the addi-
tional 3-day incubation in the present study indicates that
PRL cells were generated from preexisting GH cells and/or
MS cells that had been labeled with BrdU. Therefore, it is
 
Fig. 6.
 
Percentages of BrdU-labeled cells in GH3 cells. GH3 cells
were cultured in the control medium or in medium supplemented
with a combination of EGF, insulin and E
 
2
 
. GH3 cells were treated
with BrdU for 3 hr on day 6 or day 9 of the culture, and then immedi-
ately analyzed for BrdU-labeling (Groups I and III). The other group
of GH3 cells that had been treated with BrdU on day 6 was analyzed
for BrdU-labeling on day 9 (Group II). Data are expressed as the
mean
 
±
 
SEM of three independent experiments. ND: not detected. *
P<0.05, ** P<0.01, *** P<0.001; compared with the control of the
same group.
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highly probable that the preexisting GH or MS cells directly
transdifferentiate into PRL cells without cell division. MS
cells are thought to be transitional cells in the process of
cytogenesis of PRL cells from GH cells.
Roh 
 
et al
 
. (2001) have used a transgenic mouse system
targeting the expression of a dominant negative EGF recep-
tor to find that EGF receptor signaling is necessary for the
differentiation and/or maintenance of GH and PRL cells in
the early cytogenesis of both types of pituitary cells. EGF
treatment stimulates PRL gene-transcription and, in
contrast, decreases GH gene-transcription in GH3 cells
(Kakeya 
 
et al.
 
, 2000). These findings substantiate the notion
that EGF together with insulin and/or E
 
2
 
 is involved in the
regulation of PRL cell development. GH gene expression in
MS cells may be terminated and PRL gene expression may
be started by EGF, and finally, PRL cells (PRL only-secre-
tors) will be generated by treatment with a combination of
EGF, insulin, and E
 
2
 
.
It is well known that PRL cells have the ability to repli-
cate DNA and to divide in rat and mouse pituitary glands 
 
in
vivo
 
 and 
 
in vitro
 
 in response to estrogen and various growth
factors (Takahashi 
 
et al
 
., 1984; Oishi 
 
et al
 
., 1993; Oomizu
 
et al
 
., 2000). In contrast, it is evident from the present study
that PRL cells of GH3 cells are unable to replicate DNA mol-
ecules. The reason for this discrepancy remains unclear. It
is possible, however, that there is a difference in the heter-
ogeneity of cell populations between GH3 and normal pitu-
itary cells, although the major difference between these two
cells resides in the cell-immortality. GH3 cells consist of
homogeneous cells and are probably derived from a single
cell type. In contrast, normal pituitary cells consist of various
cell types. Several reports have indicated that an intrapitu-
itary control system, particularly cell-to-cell interactions, is
important to the regulation of pituitary function (Schwartz
and Cherny, 1992; Denef, 1994; Renner 
 
et al
 
., 1996;
Vankelecom and Denef, 1997; Schwartz, 2000). Growth fac-
tors, which are synthesized in pituitary cells, exert a regula-
tory function on pituitary cells in a paracrine manner.
Therefore, cell division in PRL cells may require various
paracrine factors produced in pituitary cells other than PRL
cells. Our recent study demonstrated that TGF-
 
α
 
 is neces-
sary for estrogen-induced proliferation of pituitary cells
(Oomizu 
 
et al
 
., 2000). Another interesting finding concerning
paracrine factors has been reported by Hentges 
 
et al
 
.
(2000). They found that basic fibroblast growth factor, pro-
duced in folliculo-stellate cells, mediates TGF-
 
β
 
3-induced
proliferation of PRL cells. From these findings, it is probable
that some factors necessary to DNA-replication and prolifer-
ation of PRL cells are deficient in GH3 cells, resulting in the
inability of PRL cells to self-duplicate.
Dopamine is well known to inhibit PRL synthesis and
release in PRL cells of the normal pituitary glands through
its receptors (Caron 
 
et al
 
., 1978). GH3 cells do not express
dopamine receptors (Cronin 
 
et al
 
., 1980). Hence, dopamine
fails to inhibit PRL synthesis and release in GH3 cells main-
tained under normal culture conditions. EGF treatment
induces the expression of dopamine receptors in GH3 cells
(Missalle 
 
et al
 
., 1990), suggesting that dopamine-inhibition
of PRL secretion begins to operate. Those previous studies
together with the present results indicate that EGF plays a
number of roles in the maturation process of PRL cells such
as in the stimulation of PRL synthesis, formation of secre-
tory granules (Scammell 
 
et al
 
., 1986), and induction of
dopamine receptors.
Mouihate and Lestage (1995) have reported that estro-
gen stimulates EGF synthesis in the rat pituitary. EGF and
its receptors are expressed in the mouse pituitary (Honda 
 
et
al
 
., 2000). EGF released from pituitary cells may act on pitu-
itary cells themselves by a paracrine or autocrine mecha-
nism. Zhang 
 
et al
 
. (1993) have found that both EGF and E
 
2
 
stimulate PRL mRNA synthesis and PRL secretion. Judging
from these previous reports, it seems possible that estrogen
action and EGF action are closely related to the develop-
ment of MS and PRL cells. As such, the regulatory mecha-
nism concerning EGF production in GH3 cells needs to be
studied.
We have recently found in mouse pituitary cells that
insulin or IGF-I stimulates the proliferation of PRL cells 
 
in
vitro
 
, and IGF-I action that is more potent than insulin action
(Oomizu 
 
et al.
 
, 1998). We also demonstrated by 
 
in situ
 
hybridization and immunocytochemistry that IGF-I and IGF-
I receptors are expressed in mouse GH cells, indicating that
pituitary IGF-I acts on GH cells in a paracrine or autocrine
manner (Honda 
 
et al
 
., 1998). Furthermore, GH3 cells
express IGF-I protein (Fagin 
 
et al
 
., 1987) and IGF-I recep-
tors (Honda 
 
et al.
 
, 1998). From these findings, it can be
assumed that the insulin action shown in the present study
may be mediated through IGF-I receptors located on GH3
cells, as insulin at high concentration is known to act on
IGF-I receptors (Houslay and Wakelam, 1988).
In conclusion, GH3 cells consist primarily of GH and MS
cells in a 5% FBS-supplemented condition. EGF, insulin,
and E
 
2
 
 are required for the development of PRL cells. MS
cells of GH3 cells are thought to be transitional cells in the
process of the transdifferentiation of GH cells into PRL cells.
In normal pituitary glands PRL cells proliferate and increase
in number in response to estrogen (Takahashi 
 
et al.
 
, 1984).
Thus, there may be at least two pathways for the growth of
PRL cells; transdifferentiation of GH cells into PRL cells, and
cell division of preexisting PRL cells.
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